Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial

[1]  J. Wójcik,et al.  A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study , 2021, Cardiology journal.

[2]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[3]  Samin K. Sharma,et al.  Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.

[4]  Yaiza Beatriz Molero-Díez,et al.  Fourth universal definition of myocardial infarction , 2019, Colombian Journal of Anesthesiology.

[5]  M. Marszałł,et al.  Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. , 2019, European heart journal. Cardiovascular pharmacotherapy.

[6]  P. Serruys,et al.  Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial , 2019, The Lancet.

[7]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[8]  P. Morange,et al.  Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study , 2017, European heart journal.

[9]  M. Hadamitzky,et al.  Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial , 2017, The Lancet.

[10]  S. de Servi,et al.  Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  Marc P. Bonaca,et al.  Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. , 2016, Journal of the American College of Cardiology.

[12]  M. Marszałł,et al.  Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial , 2015, European heart journal.

[13]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[14]  Jeroen J. Bax,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .

[15]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[16]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[17]  長尾 建,et al.  ACS(acute coronary syndrome) (特集 救急略語事典) , 2005 .